Belén Garijo, Chair of the Executive Board and CEO of Merck, shared a post on LinkedIn:
“We’ve wrapped up another solid quarter!
Our Merck Group Q3 results show that we delivered solid organic growth in net sales and EBITDA pre thanks to all three business sectors.
Our performance underscores our ability to withstand geopolitical uncertainty and strong currency headwinds. Here’s what we shared today:
1. Our Process Solutions business unit within Merck Life Science was once again the growth driver, supported by strong demand.
2. Merck Healthcare saw solid organic growth driven by our Cardiovascular, Metabolism & Endocrinology franchise, as well as by our blockbuster drugs Mavenclad and Erbitux.
3. The acquisition of SpringWorks Therapeutics had a positive impact on portfolio effects. It forms the basis for our Rare Diseases franchise.
4. The Semiconductor Materials business remains the main growth driver in Merck Electronics, benefiting from continued demand driven by the AI boom.
5. We confirmed and refined our full-year guidance for 2025.
A big thanks to all the teams! Let’s keep sprinting toward the end of the year!.”
Read more posts featuring Belén Garijo on OncoDaily.
